Download presentation
Presentation is loading. Please wait.
Published byHolger Aune Modified over 5 years ago
1
Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata, MD, Yuzo Yamamoto, MD, Taishi Harada, MD, PhD, Yoichi Nakanishi, MD, PhD, Isamu Okamoto, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 5, Pages e46-e47 (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Histologic features of the patient’s bone marrow after termination of osimertinib treatment. Hematoxylin and eosin staining revealed marked hypocellularity. Journal of Thoracic Oncology , e46-e47DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.